0001079973-13-000573.txt : 20131121 0001079973-13-000573.hdr.sgml : 20131121 20130925135551 ACCESSION NUMBER: 0001079973-13-000573 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20130925 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Venaxis, Inc. CENTRAL INDEX KEY: 0001167419 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 841553387 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1585 S. PERRY STREET CITY: CASTLE ROCK STATE: CO ZIP: 80104 BUSINESS PHONE: (303) 794-2000 MAIL ADDRESS: STREET 1: 1585 S. PERRY STREET CITY: CASTLE ROCK STATE: CO ZIP: 80104 FORMER COMPANY: FORMER CONFORMED NAME: AspenBio Pharma, Inc. DATE OF NAME CHANGE: 20051110 FORMER COMPANY: FORMER CONFORMED NAME: ASPENBIO INC DATE OF NAME CHANGE: 20020213 CORRESP 1 filename1.htm appy_corresp.htm
Correspondence
 
 
 
Venaxis, Inc.
1585 South Perry Street
Castle Rock, CO 80104
 
September 25, 2013
 
 
Via Edgar
 
P. Amy Reischauer
United States Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, NE
Mail Stop 4720
Washington, D.C. 20549
 
 
Re:
Venaxis, Inc. ("Venaxis")
Form 10-K for the Fiscal Year Ended December 31, 2012
File No. 001-33675
 
Dear Ms. Reischauer:
 
We are in receipt of the Commission’s comment letter dated September 23, 2013, regarding Venaxis’ most recent Form 10-K referenced above.  The comment letter requests that Venaxis provide a response to those comments within ten business days. We are currently working with our legal counsel and auditors to address the Commission’s comments and preparing a response. Due to travel conflicts we do not believe that we can complete a response within ten business days. As we discussed, Venaxis plans to submit a response to the Commission by October 15, 2013. Please advise us if the Commission has any objection to the time frame in which Venaxis plans to respond to the Commission’s comments. I can be reached at 303-794-2000. Alternatively our legal counsel Mary Mullany, Esq. can be reached at 215-864-8631.
 
Thank you for your attention to this request.
 
     
 
Sincerely yours,
 
 
 
VENAXIS, INC.
 
     
 
/s/ Jeff McGonegal
 
 
Chief Financial Officer